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Abstract Retinoic acid modulates growth and induces differ-
entiation and apoptosis of neuroblastoma cells in vitro, with the
all-trans and 9-cis isomers having different biological properties.
Transcriptional activation in response to retinoic acid isomers is
mediated by retinoic acid receptors and retinoid X receptors. The
differential expression of co-activators and co-repressors which
preferentially interact with retinoic acid receptors or retinoid X
receptors may be a mechanism leading to different cellular
responses to 9-cis and all-trans retinoic acid. To test this
hypothesis, we have studied the expression of the nuclear receptor
co-regulators TIF1K, TIF1L, SUG1 and SMRT in the N-type
and S-type neuroblastoma cell lines SH SY 5Y and SH S EP.
Transcripts for all four co-regulators were expressed in these
neuroblastoma cells. The expression of TIF1K, TIF1L and SUG1
did not change in response to retinoic acid; however, SMRT was
induced in both neuroblastoma cell lines, but particularly by all-
trans retinoic acid in SH S EP cells. An additional co-activator,
Trip3, was isolated by differential mRNA display and shown to
be preferentially induced by 9-cis retinoic acid in SH SY 5Y and
SH S EP cells. These data suggest that retinoic acid isomer-
specific induction of nuclear receptor co-regulators may deter-
mine, in part, the differential biological effects of retinoic acid
isomers.
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1. Introduction
Retinoic acid (RA) induces di¡erentiation, growth arrest
and apoptosis in many neuroblastoma cell lines [1,2] and in
recent clinical trials with 13-cis RA, the overall survival rates
for children treated for residual neuroblastoma following
bone marrow transplantation were signi¢cantly increased
from 20 to 40% [3,4]. In vitro studies have shown that other
RA isomers have a greater biological activity than 13-cis RA,
particularly 9-cis RA which also has distinct biological prop-
erties [5,6]. The e¡ects of RA are mediated by nuclear recep-
tors (RARs), ligand-dependent transcriptional regulators
functioning as heterodimers with auxiliary factors referred
to as retinoid X receptors (RXRs) [7,8]. In this context,
RXRs may function independently of ligand, but they can
also bind 9-cis RA with a high a⁄nity [9] and regulate gene
transcription either as 9-cis RA-dependent RXR homodimers
[10] or as heterodimers with other receptors [11,12].
The ligand-dependent activation of genes via RXRs, RARs
or other nuclear receptors depends on co-activators that in-
teract with the receptor and the pre-initiation transcription
complex. For example, the co-activator SUG1 interacts with
the RAR partner of RAR/RXR heterodimers in a ligand-de-
pendent manner [13] whereas the co-activator TIF1K appa-
rently interacts synergistically with both RAR and RXR het-
erodimer partners [13,14]. These co-activators may act either
as ‘bridging’ molecules between receptors and the basal tran-
scriptional machinery, or facilitate changes in the chromatin
structure to allow transcriptional activation. The transcrip-
tional activity of unliganded nuclear receptors is inhibited
by co-repressors such as SMRT which preferentially bind to
RARs and partially to RXRs in the absence of ligand [15].
Binding of ligand to RAR reduces the interaction with
SMRT, whereas the binding of ligand to RXR has less e¡ect
[15]. TIF1L is a co-regulator related to TIF1K but lacks the
nuclear receptor interacting domain of TIF1K and may func-
tion as a co-repressor via the KRAB domain [13]. However,
more-recent data suggest that TIF1L enhances the expression
of glucocorticoid regulated genes in a ligand- and response
element-dependent manner [16].
Since TIF1K or SUG1 di¡er in their interactions with
RARs and RXRs the relative expression of these two co-acti-
vators may determine di¡erential responses to RA isomers.
Furthermore, since RARL is induced by RA in neuroblasto-
ma cells [5,17] it may be predicted that the overall levels of
expression of co-repressors would also be regulated by RA to
maintain cellular homeostasis with respect to the ligand-de-
pendence of RARs. We have thus investigated the expression
levels and responses to di¡erent retinoic acid isomers of co-
regulators TIF1K, SUG1, TIF1L and SMRT in the SH SY 5Y
and SH S EP cell lines, representing neuroblast (N-type) and
substrate adherent (S-type) neuroblastoma cells derived from
the mixed parental cell line SK N SH (in which both pheno-
types are represented) [18], and report the identi¢cation of an
additional retinoic acid-induced co-activator expressed in
these neuroblastoma cells.
2. Materials and methods
2.1. Cell culture and treatment with retinoic acid isomers
SH SY 5Y (N-type) and SH S EP (S-type) neuroblastoma cells were
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grown in Dulbecco’s modi¢cation of Eagles medium, supplemented
with 10% fetal bovine serum (Sera Lab, Crawley, UK) (culture me-
dium) in a humidi¢ed atmosphere of 5% CO2 in air. Prior to treat-
ment with either 9-cis or all-trans RA, 8U106 cells were seeded into 75
cm2 tissue culture £asks (Costar, Bucks, UK) and cultured overnight.
9-cis or all-trans RA (Sigma Chemical Company, Poole, UK) were
added in ethanol to a ¢nal concentration of 1036 M. An equal volume
of ethanol (6 0.1% of the culture volume) was used to treat the con-
trol cells. Cultures were incubated in the presence of retinoids for 2^48
h prior to RNA extraction.
2.2. Extraction of RNA, size fractionation and Northern blotting
Total cellular RNA for Northern blotting was extracted by lysing
cells in a guanidinium isothiocyanate solution followed by extraction
with 1:1 phenol/chloroform [19]. RNA was concentrated by precip-
itation in isopropanol and size fractionated (20 Wg per track) through
glyoxal/DMSO gels [20], transferred to nylon membranes (Hybond,
Amersham Bucks, UK) by vacuum blotting and ¢xed by treatment
with UV light. For analysis by di¡erential mRNA display, total cel-
lular RNA was prepared from SH SY 5Y cells by lysis with guanidine
thiocyanate and ultracentrifugation [21] at 230 000Ug for 3 h at 18‡C
(Beckman TLA 120.2 ¢xed angle rotor). Pelleted RNA was extracted
three times with 1:1 phenol:chloroform [22], once with chloroform
and ethanol precipitated at 320‡C. After digestion with RNase-free
DNase (Message Clean, Genehunter Corp., Nashville, TN, USA),
RNA was stored in 3 Wl aliquots at a concentration of 1 Wg/Wl at
320‡C. For the RNase protection assays, total cytoplasmic RNA
was extracted [22].
2.3. Probing of Northern blots with [32P]-labelled cDNA probes
Northern blots were probed with [K32P]dCTP (Amersham)-labelled
cDNA probes for SMRT, SUG1, TIF1L, TIF1K and GAPDH (load-
ing control) [23] or with a riboprobe for Trip3 isolated from di¡er-
ential display experiments. Pre-hybridization and hybridization of the
Trip3 riboprobe, prepared as for RNase protection assays was per-
formed at 60‡C using 7U104 cpm in 15 ml of hybridization bu¡er.
cDNA probes were inserts from EST clones obtained from
I.M.A.G.E. consortium (LLNL) and their identities were con¢rmed
by sequence analysis (Table 1). Blots were exposed to X-ray ¢lm and
the autoradiographic images scanned for the measurement of band
intensity using Quantiscan software (Version 1.5, Elsevier Biosoft).
Band intensities were corrected for GAPDH loading and expressed
relative to control, untreated cells. The data were analyzed using
robust, non-parametric statistics and are presented in the ¢gures as
medians and ranges.
2.4. Di¡erential mRNA display
2 Wg RNA was reverse transcribed using, poly (T18A, G, or C)
primers, Superscript II reverse transcriptase (Life Technologies, Pais-
ley, UK) and the RNA Image mRNA Di¡erential Display system
(GeneHunter) [24]. Primers for PCR were poly(T18A) and
CCGAATTCTGGTTCCAAAACCG primers for the upstream or 5P
primer. PCR products were analyzed by electrophoresis through non-
reducing sequencing gels and autoradiographed. Di¡erentially-ex-
pressed bands were reampli¢ed by PCR and cloned into the pCR2.1
cloning vector (Invitrogen, Leek, The Netherlands). After transforma-
tion into Escherichia coli (TOP10FP) and the preparation of plasmid
DNA, cloned inserts were sequenced in forward and reverse orienta-
tion using an Applied Biosystems DNA sequencer in the University of
Newcastle Facility for Molecular Biology [24]. Sequence data were
compared against sequences in the non-redundant Genbank and
EST databases using the BLASTN program [25].
2.5. RNase protection assays
RNase protection assays were performed using the Ambion RNase
protection assay kit (Ambion, AMS Biotechnology, Oxford). 1 Wg of
plasmid cDNA containing a Trip3 insert was linearized and a ribo-
probe prepared in a reaction mix consisting of T7 polymerase,
5Ubu¡er, 4 Wl of 2.5 M ribonucleotide triphosphates (GTP, UTP
and ATP), 1 Wl of RNasin (40 U/Wl), 2 Wl 100 mM dithiothreitol,
2 Wl of distilled water and 5 Wl of radio-labelled [K32P]CTP (Amersham).
After incubation for 1 h at 37‡C, 2 U of DNase I were added and the
reaction was incubated for a further 15 min at 37‡C. After extraction
with 1:1 phenol:chloroform and once with chloroform, the riboprobe
(7U104 counts/reaction) and test RNA (7.5 Wg) were precipitated
together at 320‡C for 15 min with 0.5 M sodium acetate and 2.5
volumes of absolute ethanol, centrifuged at 13 000 rpm for 10 min
at room temperature and redissolved in 20 Wl of solution A from the
RNase protection assay kit. The samples were then heated brie£y for
3^4 min at 95‡C before being hybridized overnight at 43‡C. Following
digestion with RNase A (1:50 dilution of stock) for 30 min at 37‡C,
samples were precipitated (320‡C for 15 min), resuspended in loading
bu¡er and separated by electrophoresis through 0.4 mm 6% non-re-
ducing sequencing gels. Dried gels were autoradiographed at 380‡C
overnight.
3. Results
3.1. Expression of TIF1K, TIF1L, SUG1 and SMRT in SH SY
5Y and SH S.EP neuroblastoma cells
The expression of TIF1L, SUG1 and SMRT was readily
detectable in SH SY 5Y and SH S EP cells (Figs. 1^3):
SMRT mRNA was visible as a band running above the 28S
rRNA, consistent with its reported transcript size of 5.9^6.0
kb [26], TIF1L mRNA was approximately 3.0 kb in length,
running between 18S and 28S rRNA, whereas the SUG1
probe detected a single transcript between 18S rRNA and
the 1.3 kb GAPDH mRNA (reported transcript size 1.4 kb
[27]) (Fig. 1). TIF1K was also expressed but was only just
detectable on Northern blots (data not shown) as a band
running just ahead of 28S rRNA, consistent with its reported
size of 4.5 kb [28]. Compared to TIF1K, SUG1 and TIF1L
gave strong signals on Northern blots, suggesting that they
were expressed at a higher level than TIF1K in these cells.
After treatment of SH S EP cells for up to 48 h with either
all-trans or 9-cis RA at 1036 M, there was a clear induction of
SMRT mRNA in response to RA relative to control, ethanol-
treated cells (data of Fig. 1 and two additional independent
experiments: Kruskall-Wallis one-way ‘analysis of variance’
on control, 9-cis and all-trans RA-treated cells, all time points
combined, P6 0.001: all-trans RA versus control, Mann-
Whitney U-test, P6 0.002). Induction of SMRT mRNA was
detectable after 2 h and reached up to 5-fold after 16^24 h
with all-trans RA, before declining over the next 24 h (Fig. 2).
Although SMRT was induced in response to both 9-cis and
all-trans RA, all-trans RA gave a signi¢cantly greater induc-
tion than 9-cis RA overall (9-cis RA versus all-trans RA, all
time points combined, Mann-Whitney U-test P6 0.05): 9-cis
RA induced SMRT after 2 h but SMRT mRNA levels
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Table 1
EST clones used for probes
Probe Insert (kb) Extent1 Source2 Clone ID EST name
TIF1K 1.6 3PUTR+6 0.5 CDS IMAGE 446686 zx58a12.r1
TIF1L 1.0 3PUTR+0.25 CDS IMAGE 265340 yx52a11.r1
SUG1 1.3 3PUTR+CDS ATCC EST188567
SMRT 0.5 3PUTR IMAGE 145024 yi74g09.r1
1UTR, untranslated region; CDS, coding sequence.
2IMAGE, I.M.A.G.E. Consortium, Lawrence Livermore National Laboratory, Livermore, CA; ATCC, American Tissue Culture Collection.
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reached a plateau after 4 h with little subsequent change.
Conversely, there was no signi¢cant induction of either
SUG1 or TIF1L (Fig. 2) or TIF1K (data not shown) over
48 h of treatment with 9-cis or all-trans RA. SH SY 5Y cells
showed a similar pattern of SMRT induction relative to
TIF1L and SUG1 but in these cells there was no signi¢cant
di¡erence between all-trans and 9-cis RA (Fig. 3).
3.2. Identi¢cation of Trip3 as a RA regulated co-activator in
neuroblastoma cells
A di¡erential display analysis carried out to identify the
genes regulated by di¡erent RA isomers resulted in the iden-
ti¢cation of a 135 bp cDNA fragment preferentially induced
by 1 WM 9-cis RA after 6 h. A BLASTN search of the EMBL/
Genbank database [25] with the sequence of this cDNA gave
an exact match to bases 166^300 of the putative co-activator
Trip3 (EMBL accession number L40410) [29]. Since this is
within the encoding sequence of Trip3 and not the 3PUTR
as expected from the di¡erential display strategy, this cDNA
presumably resulted from internal priming during the cDNA
synthesis or PCR steps.
Induction of Trip3 in response to 9-cis RA was con¢rmed
by RNase protection assays using the 135 bp Trip3 cDNA
cloned into the pCR2.1 vector, as a probe. In three independ-
ent experiments, SH SY 5Y cells were treated with 1 WM all-
trans or 9-cis RA for 6 h. Relative to control cells, Trip3 was
consistently induced by 9-cis RA: all-trans RA also induced
Trip3 but compared to induction by 9-cis RA the response
was minimal (Fig. 4). Trip3 was also expressed in SH S EP
cells and markedly induced by 9-cis RA but to a lesser extent
by all-trans RA (Fig. 4).
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Fig. 2. Time course of SMRT, SUG1 and TIF1L expression in SH
S EP S-type neuroblastoma cells. Each point is the median induc-
tion relative to control (t = 0) cells (error bars are the ranges) for
three replicates (data of Fig. 1 and two additional independent ex-
periments), except controls for which n = 6.
Fig. 1. Northern blot of SMRT, TIF1L, SUG1 and GAPDH ex-
pression in SH S EP neuroblastoma cells treated for 2, 4, 8, 16, 24
or 48 h with 1 WM 9-cis or all-trans RA. Quanti¢cation of these
data are summarized in Fig. 2 together with the data from two ad-
ditional independent experiments.
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4. Discussion
The results of this study show that SMRT, SUG1, TIF1K
and TIF1L were all expressed in S-type SH S EP and N-type
SH SY 5Y neuroblastoma cells, although expression of TIF1K
was barely detectable. SMRT and SUG1 (Trip1) are also ex-
pressed in the SK N BE, SMS KCNR and IMR32 neuro-
blastoma cell lines [30]. Since RAR-L is induced by RA in
neuroblastoma cells [5,17], the induction of SMRT in re-
sponse to all-trans and 9-cis RA supports the idea that co-
repressor expression is co-induced to maintain ligand-depend-
ence of particular nuclear receptors. SMRT induction in re-
sponse to RA was rapid, detectable within 2 h, implying a
direct transcriptional e¡ect, although there are, as yet, no data
identifying retinoic acid response elements within the SMRT
promoter. Whether the induction of co-repressors is a general
phenomenon linking changes in nuclear receptor expression
with concomitant changes in co-repressor expression, is not
known at present. As well as potentially maintaining homeo-
stasis between nuclear receptors and co-repressors, the induc-
tion of SMRT by RA may have other consequences. For
example, when overexpressed in primary synovial ¢broblasts,
SMRT inhibits the expression of matrix metalloproteinase-1
independently of hormone response elements [31]. Thus, this
may be a mechanism whereby RA has indirect, RAR-inde-
pendent e¡ects on cellular responses. Furthermore, since the
agonist/antagonist activity of synthetic receptor ligands such
as anti-oestrogens (tamoxifen, 4-hydroxytamoxifen) and anti-
progestins (RU486), can be modulated by altering the co-re-
pressor/co-activator ratio [32,33], the induction of SMRT in
response to RA may have important consequences for reduc-
ing unwanted agonist activity of anti-oestrogens and anti-pro-
gestins in a clinical setting. This implies that SMRT may also
have a role in modulating the agonist/antagonist activities of
synthetic retinoids.
Since our data show no apparent change in the expression
of the co-activators SUG1 and TIF 1K in response to either
RA isomer, the level of these co-activators could limit ligand-
dependent gene regulation, but further studies will be required
to examine the stoichiometry of co-activators and nuclear
receptors. SUG1 preferentially interacts with RARs in
RAR-RXR heterodimers [13,14] and the relatively high level
of expression of SUG1 compared to TIF1K in these neuro-
blastoma cells suggests that responses to RA will be mediated
mainly via the RAR partner. However, other co-activators
may be important in mediating ligand-dependent e¡ects via
both RARs and RXRs and this question needs to be ad-
dressed in neuroblastoma cells by performing two hybrid
screens to assess qualitatively and quantitatively which co-
regulators are important in mediating retinoid responses.
Trip3 is a potential co-activator that may mediate RA-de-
pendent e¡ects. Other than the fact that Trip3 is expressed
in a range of tissues, including neural tissue, and that it con-
tains a transcriptional activation domain [29], little is known
of the function of this gene product. The fact that Trip3 was
preferentially induced by 9-cis RA relative to all-trans RA,
whereas SMRT was preferentially induced by all-trans RA
in SH S EP cells, suggests that di¡erential regulation of co-
regulators could be a factor underlying the di¡erential bio-
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Fig. 4. The RNase protection assay for transcripts complementary
to Trip3. RNA (7.5 Wg) was extracted from cells treated for 6 h
with 1 WM all-trans (at) or 9-cis RA (9c) or control ethanol (C) and
hybridized with [32P]-labelled riboprobes complementary to Trip3.
The protected 135 base fragment corresponding to Trip3 ran just
below the 147 base marker (arrow). An apparent di¡erence in size
between bands in the SH S EP cell experiment is a gel running arti-
fact.
Fig. 3. Time course of SMRT, SUG1 and TIF1L expression in N-
type SH SY 5Y neuroblastoma cells. Each point is the median in-
duction relative to control (error bars are the ranges) for three repli-
cates, except controls where n = 6 and the SMRT results where each
point represents the mean of duplicate experiments.
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logical e¡ects of 9-cis RA and all-trans RA. This further em-
phasizes the importance of detailed studies of co-regulator
stoichiometry to elucidate the mechanisms of di¡erent RA
isomers and RA analogues in neuroblastoma cells.
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